Wall Street analyst estimates for Spero Therapeutics, Inc. (SPRO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 5 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 13 |
| Avg rating (1-5) | 0.31 |
Valuation Ratios
| P/E Ratio | 7.93 |
| Price / Book | 1.46 |
| EV / EBITDA | 2.77 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $335000 | $2.0M | $4.0M | $18.1M | $9.3M | $3.1M | $48.6M | $103.8M | $48.0M | $59.6M |
| Cost of Revenue | $26.3M | $32.9M | $33.9M | $65.8M | $67.0M | 0 | 0 | $51.4M | $96.8M | 0 |
| Gross Profit | -$26.0M | -$30.9M | -$29.9M | -$47.6M | -$57.7M | $3.1M | $48.6M | $52.3M | -$48.8M | $59.6M |
| Research & Development | $26.3M | $32.9M | $33.9M | $67.9M | $69.4M | $64.5M | $47.6M | $51.4M | $96.8M | $38.5M |
| Selling, General & Admin | $7.2M | $10.8M | $12.9M | $15.6M | $21.4M | $41.7M | $36.5M | $25.6M | $23.7M | $21.2M |
| Operating Expenses | $33.6M | $41.7M | $42.8M | $15.6M | $21.4M | $91.0M | $90.8M | $30.9M | $24.6M | $59.6M |
| Operating Income | -$33.2M | -$41.7M | -$42.8M | -$63.2M | -$79.1M | -$88.0M | -$42.2M | $21.5M | -$73.4M | -$24000 |
| EBITDA | -$32.9M | -$41.4M | -$42.4M | -$62.5M | -$78.4M | -$87.2M | -$42.9M | $27.2M | -$72.5M | $8.8M |
| Interest Expense | 0 | $303000 | $303000 | 0 | 0 | $1.9M | $2.6M | 0 | 0 | 0 |
| Pre-tax Income | -$32.6M | -$46.1M | -$41.7M | -$60.9M | -$78.3M | -$89.8M | -$46.4M | $25.4M | -$68.6M | $8.8M |
| Income Tax | 0 | -$363000 | 0 | 0 | 0 | 0 | 0 | $2.6M | 0 | $261000 |
| Net Income | -$25.5M | -$46.1M | -$41.7M | -$60.9M | -$78.3M | -$89.8M | -$46.4M | $22.8M | -$68.6M | $8.6M |
| EPS | $-3.86 | $-17.82 | $-2.60 | $-3.31 | $-3.52 | $-2.91 | $-1.23 | $0.43 | $-1.27 | $0.15 |
| EPS (Diluted) | $-3.86 | $-17.82 | $-2.60 | $-3.31 | $-3.52 | $-2.91 | $-1.23 | $0.43 | $-1.27 | $0.15 |
| Shares Outstanding (Diluted) | $6.6M | $2.6M | $16.0M | $18.2M | $22.4M | $30.9M | $37.6M | $53.0M | $54.0M | $59.0M |
Price
| Price | $1.11 |
| Market Cap | $64M |
| Exchange | NASDAQ |
| Country | US |
Explore sector: Healthcare · Biotechnology
More sections of SPRO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks